Noah Fishbein’s Post

#WorldParkinsonsDay is an opportunity for us to highlight three projects we have established and evaluated over the past year, each with a specific focus on improving the quality of life for people with Parkinson's disease: 💪EMPOWER-PD: Development, testing and evaluation of an 8-week Self-management program tailored People with Parkinson`s disease in a multi-center, cross-sectoral, intervention study ⌚️PD-DigiCare: Enhancing referral decision-making for advanced treatment in Parkinson's Disease through objective measurements and patient reported outcomes - a multicentre randomized controlled trial. 💊Home-based titration with Duodenal infusion of Levodopa-carbidopa intestinal gel in People with Parkinson’s disease: an observational feasibility study The latter project was a collaborative effort conducted at the #Movement disorder Clinic at Rigshospitalet and was published recently. It can be read in full publication here: https://lnkd.in/d_mRTqCm These initiatives represent our commitment to advancing Parkinson's disease management and improving the lives of those affected by the chronic condition. Bo Biering-Sørensen Nikolaj Folke la Cour Karottki Marc Klee Olsen Mahsa Javidi Nick Schou Nielsen Asher Lou Isenberg Jeanet Vilhelmsen Emma Lindström

For those who have asked me about the policy work I have been doing in the Alzheimer’s disease space, here is the PubMed link to my first, first-author paper, titled “Diagnostic Hesitancy of Primary Care Physicians in Puerto Rico Towards Alzheimer’s Disease: Opportunities for Transformation”, published in September. The findings of this study, with 100+ Puerto Rican PCPs, highlights the need to better prepare for the challenges of diagnosis and management of ADRD, when the “brain drain” of specialists is putting Puerto Rican PCPs at the helm of dealing with a growing ADRD epidemic. Addressing challenges faced by PCPs in diagnosing and managing ADRD is essential to ensure timely and accurate diagnosis –and appropriate care–for people living with the disease. National Institute on Aging (NIA) https://lnkd.in/g6KkAx-2

My first article

The PROFILE trial reveals groundbreaking results in Crohn's disease treatment, emphasizing early intervention with advanced therapy for improved outcomes. https://lnkd.in/dUqVJsKA . . . . #CrohnsDisease #PROFILEtrial #InflammatoryBowelDisease #Gastroenterology #MedicalResearch #HealthcareInnovation #PatientCare #TreatmentAdvances #ClinicalTrials #DiseaseManagement #QualityOfLife #HealthScience #DigestiveHealth #MedicalBreakthrough #HopeForPatients

Fantastic to see LifeArc investing £40m in research centres in the UK focused on rare diseases. There are going to be four conceptual centres, each with a specific focus: (i) respiratory diseases; (ii) kidney diseases; (iii) mitochondrial diseases; and (iv) the acceleration of rare disease trials. The last one is particularly interesting and includes creating "a rare disease trial recruitment portal and will design and deliver trials in partnership with patients". It looks like each centre will involve a number of different academic institutions and NHS trusts to help harness the best of the rare disease community in the UK. LifeArc have excelled over the last 10 years or so in early-stage translation in the UK. There is significant unmet need in rare diseases and so I'm looking forward to seeing the impact of this investment. https://lnkd.in/eYqrUZJY #raredisease #medicalresearch #lifesciences

Dr. Michael Pulia, associate professor of emergency medicine, will be a co-principal investigator with Dr. Hilary Faust, assistant professor, University of Wisconsin Department of Medicine, on a Wisconsin Partnership grant seeking to identify a unique molecular signature for lung injury due to aspiration and facilitate the development of precision therapies for aspiration pneumonia. Pneumonia is the leading infectious cause of mortality in older adults and about 15% of cases are due to aspiration pneumonia, which currently lacks objective diagnostic criteria and methodology for identifying high-risk patients. The project could inform the identification of effective interventions for aspiration pneumonia and promote improved health outcomes for at-risk older adults throughout Wisconsin and beyond. https://lnkd.in/g68jBrwJ

**Inflammatory Markers, Frailty, and Mortality in Older COVID-19 Patients** 🏥🔬 A recent study highlights the critical link between inflammatory markers and frailty in older COVID-19 patients, revealing their significant impact on in-hospital mortality. Elevated inflammatory markers were associated with increased frailty and a higher risk of death, underscoring the need for targeted interventions to manage inflammation and improve outcomes in this vulnerable population. #COVID19 #GeriatricMedicine #Inflammation

Many advances have been developed in the last few years in attempts to decrease proteinuria and delay Chronic Kidney Disease in our IgA Nephropathy patients. Come check out this AJKD Blog on the recent advances in IgA management. Happy to have worked on this with Shane Bobart, MD, FASN! The future is here!

Article alert from the Journal of Comparative Effectiveness Research: Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA Using the IQVIA PharMetrics Plus and AEMR databases, this study evaluates all-cause and liver-associated healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with #liverdisease and/or #lungdisease. Authors: May Hagiwara, PhD, Suna Park, Ed Marins and Kaili Ren (Takeda), Victoria Divino and Mark DeLegge, MD, FACG, CNSP, AGAF, FASGE (IQVIA), and Charlie Strange (Medical University of South Carolina) #heor #healtheconomics #claimsdata

Check out the latest publication by Jan M. Heijdra Suasnabar in Gastroenterology!